The medicine contained 50 milligrams of semaglutide, about 20 times as much as in the strongest dose of the weekly Wegovy injection. Novo already sells a pill for diabetes under the name Rybelsus ...

William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

Patients on the once-weekly 7.2 milligram dose of Novo's drug for 72 weeks lowered their weight by 20.7% during the trial, compared with 17.5% for the 2.4 milligram dose and 2.4% for the placebo.

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Novo Nordisk has had a setback in its quest to develop an insulin pill, CEO Lars Rebien Sorensen has revealed, saying the drug would be too expensive for payers to stomach in its current form.